RxDoctor Payments Data

Junghwan Choi, MD

Urology · Garden Grove, CANPI 1255391710

Payments from drug & device makers

$6,651in general payments, 2019–2025

Across 67 payments — averaging $99.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$4K
  • Neotract Inc.$2K
  • Johnson & Johnson$558
  • Pfizer$439
  • Medtronic$137
  • Novo Nordisk$125
  • plus $158 from 4 others

What the payments were for

  • Travel & lodging$3,23449%
  • Food & beverage$3,41851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teleflex LLC28$3,731
Neotract Inc.13$1,504
Johnson & Johnson5$558
Pfizer13$439
Medtronic1$137
Novo Nordisk1$125
Agiliti Surgical, Inc.1$65
AbbVie(2 entities)2$39
Olympus America Inc.1$29
Astellas Pharma US Inc2$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,651 in reported general payments places this provider in the 65th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$111,815
Medicare patients
244
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate42$213,940
MyrbetriqMirabegron60$37,773
Tolterodine Tartrate ErTolterodine Tartrate111$5,399
Tamsulosin Hcl396$4,229
Doxazosin Mesylate410$3,829
Finasteride413$3,290
Oxybutynin Chloride352$2,789
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst31$1,170
Solifenacin Succinate46$1,127
Cephalexin20$720
Bicalutamide35$568
Levofloxacin200$438
Doxycycline Monohydrate31$370
Bethanechol Chloride13$291
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim69$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLupron Depot$39$213,94042 claims
Astellas Pharma US IncMyrbetriq$25$37,77360 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,324 urology providers in California.

Other urology in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →